• Sama Anvari, Kayla Dadgar, Ciarán Galts, and Michael Bretthauer.
• Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada (S.A., K.D., C.G.).
• Ann. Intern. Med. 2024 May 1; 177 (5_Supplement): S27S36S27-S36.

AbstractThis article summarizes clinically important gastroenterology developments from 2023 for internal medicine specialists. In colorectal cancer screening, a new RNA fecal screening test is on the horizon, as well as a new analysis on the benefits of using artificial intelligence in screening colonoscopy to detect more polyps. There is new evidence for management of gastrointestinal bleeding, a new drug for treatment of recurrent small-intestinal angiodysplasia, and a new endoscopic treatment method in patients with gastrointestinal tumor bleeding. The authors feature a randomized trial about amitriptyline as treatment for patients with irritable bowel syndrome by primary care providers and bring you news about new biologic agents for inflammatory bowel disease and eosinophilic esophagitis. Finally, they review 2 important articles on new terminology and management of metabolic dysfunction-associated fatty liver disease.

31 keywords...

hide…